Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this rev...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2017-04, Vol.13 (4), p.867-876 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 876 |
|---|---|
| container_issue | 4 |
| container_start_page | 867 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 13 |
| creator | Thommes, Edward W. Kruse, Morgan Kohli, Michele Sharma, Rohita Noorduyn, Stephen G. |
| description | In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this review (GSK study identifier: HO-13-14054) is to examine the epidemiology and disease burden of influenza in Canada and the economic benefits of vaccination. To inform this review, we performed a systematic literature search of relevant Canadian literature and National surveillance data. Influenza B viruses from phylogenetically-distinct lineages (B/Yamagata and B/Victoria) co-circulate in Canada, and are an important cause of influenza complications. Modeling studies, including those postdating the search suggest that switching from TIV to QIV in Canada reduces the burden of influenza and would likely be cost-effective. However, more robust real-world outcomes data is required to inform health policy decision makers on appropriate influenza vaccination strategies for Canada. |
| doi_str_mv | 10.1080/21645515.2016.1251537 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5404371</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4ecf33f225b145baa353648f5c6e19c6</doaj_id><sourcerecordid>1841804426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-a344b082e51033cac2ff1a17b0e1ce84b424163d79d72bc275e63a44b5b506fc3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEolXpTwDlyCWLP5MsBwSs-KhUCQmBxM2a2OPWlddu7SRVufLHcdjtqr3gi0cz7zxja96qeknJipKevGG0FVJSuWKEtivKSsi7J9Xxkm-kFL-eHmIqj6rTnK9IOR1hom2fV0es62Uvyfq4-vMdZ4e3dbR1RsgxgK9dsH7C8BtKVG8ggIG39ccpGQyLzrhFiTUEU4-XWOuYxwatRT26GQPmvKhuJjDJzeAxjIUDSxFGNA_oM2jtiv5F9cyCz3i6v0-qn58__dh8bc6_fTnbfDhvtORibIALMZCeoaSEcw2aWUuBdgNBqrEXg2CCttx0a9OxQbNOYsuh9MhBktZqflKd7bgmwpW6Tm4L6U5FcOpfIqYLBWl02qMSqC3nljE5UCEHAC55K3ordYt0rdvCerdjXU_DFo0uv0zgH0EfV4K7VBdxVlIQwTtaAK_3gBRvJsyj2rqs0XsIGKesaC9oT4Rgyyy5k-oUc05oD2MoUYsf1L0f1OIHtfdD6Xv18I2HrvvtF8H7naDsJKYt3MbkjRrhzsdkEwTtsuL_n_EXsRnHNw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841804426</pqid></control><display><type>article</type><title>Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Thommes, Edward W. ; Kruse, Morgan ; Kohli, Michele ; Sharma, Rohita ; Noorduyn, Stephen G.</creator><creatorcontrib>Thommes, Edward W. ; Kruse, Morgan ; Kohli, Michele ; Sharma, Rohita ; Noorduyn, Stephen G.</creatorcontrib><description>In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this review (GSK study identifier: HO-13-14054) is to examine the epidemiology and disease burden of influenza in Canada and the economic benefits of vaccination. To inform this review, we performed a systematic literature search of relevant Canadian literature and National surveillance data. Influenza B viruses from phylogenetically-distinct lineages (B/Yamagata and B/Victoria) co-circulate in Canada, and are an important cause of influenza complications. Modeling studies, including those postdating the search suggest that switching from TIV to QIV in Canada reduces the burden of influenza and would likely be cost-effective. However, more robust real-world outcomes data is required to inform health policy decision makers on appropriate influenza vaccination strategies for Canada.</description><identifier>ISSN: 2164-5515</identifier><identifier>ISSN: 2164-554X</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2016.1251537</identifier><identifier>PMID: 27858509</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>burden ; Canada - epidemiology ; Cost of Illness ; Cost-Benefit Analysis ; costs ; epidemiology ; hospitalization ; Humans ; influenza ; influenza vaccine ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - economics ; Influenza Vaccines - immunology ; Influenza, Human - economics ; Influenza, Human - epidemiology ; Influenza, Human - prevention & control ; lineage-mismatch ; Models, Statistical ; quadrivalent ; Review ; Vaccination - economics ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - economics ; Vaccines, Inactivated - immunology ; Victoria</subject><ispartof>Human vaccines & immunotherapeutics, 2017-04, Vol.13 (4), p.867-876</ispartof><rights>2017 The Author(s). Published with license by Taylor & Francis © Edward W. Thommes, Morgan Kruse, Michele Kohli, Rohita Sharma, and Stephen G. Noorduyn 2017</rights><rights>2017 The Author(s). Published with license by Taylor & Francis 2017 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-a344b082e51033cac2ff1a17b0e1ce84b424163d79d72bc275e63a44b5b506fc3</citedby><cites>FETCH-LOGICAL-c534t-a344b082e51033cac2ff1a17b0e1ce84b424163d79d72bc275e63a44b5b506fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404371/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404371/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27858509$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thommes, Edward W.</creatorcontrib><creatorcontrib>Kruse, Morgan</creatorcontrib><creatorcontrib>Kohli, Michele</creatorcontrib><creatorcontrib>Sharma, Rohita</creatorcontrib><creatorcontrib>Noorduyn, Stephen G.</creatorcontrib><title>Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this review (GSK study identifier: HO-13-14054) is to examine the epidemiology and disease burden of influenza in Canada and the economic benefits of vaccination. To inform this review, we performed a systematic literature search of relevant Canadian literature and National surveillance data. Influenza B viruses from phylogenetically-distinct lineages (B/Yamagata and B/Victoria) co-circulate in Canada, and are an important cause of influenza complications. Modeling studies, including those postdating the search suggest that switching from TIV to QIV in Canada reduces the burden of influenza and would likely be cost-effective. However, more robust real-world outcomes data is required to inform health policy decision makers on appropriate influenza vaccination strategies for Canada.</description><subject>burden</subject><subject>Canada - epidemiology</subject><subject>Cost of Illness</subject><subject>Cost-Benefit Analysis</subject><subject>costs</subject><subject>epidemiology</subject><subject>hospitalization</subject><subject>Humans</subject><subject>influenza</subject><subject>influenza vaccine</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - economics</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza, Human - economics</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - prevention & control</subject><subject>lineage-mismatch</subject><subject>Models, Statistical</subject><subject>quadrivalent</subject><subject>Review</subject><subject>Vaccination - economics</subject><subject>Vaccines, Inactivated - administration & dosage</subject><subject>Vaccines, Inactivated - economics</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Victoria</subject><issn>2164-5515</issn><issn>2164-554X</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1v1DAQhiMEolXpTwDlyCWLP5MsBwSs-KhUCQmBxM2a2OPWlddu7SRVufLHcdjtqr3gi0cz7zxja96qeknJipKevGG0FVJSuWKEtivKSsi7J9Xxkm-kFL-eHmIqj6rTnK9IOR1hom2fV0es62Uvyfq4-vMdZ4e3dbR1RsgxgK9dsH7C8BtKVG8ggIG39ccpGQyLzrhFiTUEU4-XWOuYxwatRT26GQPmvKhuJjDJzeAxjIUDSxFGNA_oM2jtiv5F9cyCz3i6v0-qn58__dh8bc6_fTnbfDhvtORibIALMZCeoaSEcw2aWUuBdgNBqrEXg2CCttx0a9OxQbNOYsuh9MhBktZqflKd7bgmwpW6Tm4L6U5FcOpfIqYLBWl02qMSqC3nljE5UCEHAC55K3ordYt0rdvCerdjXU_DFo0uv0zgH0EfV4K7VBdxVlIQwTtaAK_3gBRvJsyj2rqs0XsIGKesaC9oT4Rgyyy5k-oUc05oD2MoUYsf1L0f1OIHtfdD6Xv18I2HrvvtF8H7naDsJKYt3MbkjRrhzsdkEwTtsuL_n_EXsRnHNw</recordid><startdate>20170403</startdate><enddate>20170403</enddate><creator>Thommes, Edward W.</creator><creator>Kruse, Morgan</creator><creator>Kohli, Michele</creator><creator>Sharma, Rohita</creator><creator>Noorduyn, Stephen G.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170403</creationdate><title>Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines</title><author>Thommes, Edward W. ; Kruse, Morgan ; Kohli, Michele ; Sharma, Rohita ; Noorduyn, Stephen G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-a344b082e51033cac2ff1a17b0e1ce84b424163d79d72bc275e63a44b5b506fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>burden</topic><topic>Canada - epidemiology</topic><topic>Cost of Illness</topic><topic>Cost-Benefit Analysis</topic><topic>costs</topic><topic>epidemiology</topic><topic>hospitalization</topic><topic>Humans</topic><topic>influenza</topic><topic>influenza vaccine</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - economics</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza, Human - economics</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - prevention & control</topic><topic>lineage-mismatch</topic><topic>Models, Statistical</topic><topic>quadrivalent</topic><topic>Review</topic><topic>Vaccination - economics</topic><topic>Vaccines, Inactivated - administration & dosage</topic><topic>Vaccines, Inactivated - economics</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Victoria</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thommes, Edward W.</creatorcontrib><creatorcontrib>Kruse, Morgan</creatorcontrib><creatorcontrib>Kohli, Michele</creatorcontrib><creatorcontrib>Sharma, Rohita</creatorcontrib><creatorcontrib>Noorduyn, Stephen G.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thommes, Edward W.</au><au>Kruse, Morgan</au><au>Kohli, Michele</au><au>Sharma, Rohita</au><au>Noorduyn, Stephen G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2017-04-03</date><risdate>2017</risdate><volume>13</volume><issue>4</issue><spage>867</spage><epage>876</epage><pages>867-876</pages><issn>2164-5515</issn><issn>2164-554X</issn><eissn>2164-554X</eissn><abstract>In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6-23 months and trivalent inactivated influenza vaccines (TIVs) or QIVs in adults. The objective of this review (GSK study identifier: HO-13-14054) is to examine the epidemiology and disease burden of influenza in Canada and the economic benefits of vaccination. To inform this review, we performed a systematic literature search of relevant Canadian literature and National surveillance data. Influenza B viruses from phylogenetically-distinct lineages (B/Yamagata and B/Victoria) co-circulate in Canada, and are an important cause of influenza complications. Modeling studies, including those postdating the search suggest that switching from TIV to QIV in Canada reduces the burden of influenza and would likely be cost-effective. However, more robust real-world outcomes data is required to inform health policy decision makers on appropriate influenza vaccination strategies for Canada.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>27858509</pmid><doi>10.1080/21645515.2016.1251537</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2017-04, Vol.13 (4), p.867-876 |
| issn | 2164-5515 2164-554X 2164-554X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5404371 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | burden Canada - epidemiology Cost of Illness Cost-Benefit Analysis costs epidemiology hospitalization Humans influenza influenza vaccine Influenza Vaccines - administration & dosage Influenza Vaccines - economics Influenza Vaccines - immunology Influenza, Human - economics Influenza, Human - epidemiology Influenza, Human - prevention & control lineage-mismatch Models, Statistical quadrivalent Review Vaccination - economics Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - economics Vaccines, Inactivated - immunology Victoria |
| title | Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A41%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20seasonal%20influenza%20in%20Canada:%20Burden%20of%20disease%20and%20the%20cost-effectiveness%20of%20quadrivalent%20inactivated%20influenza%20vaccines&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Thommes,%20Edward%20W.&rft.date=2017-04-03&rft.volume=13&rft.issue=4&rft.spage=867&rft.epage=876&rft.pages=867-876&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2016.1251537&rft_dat=%3Cproquest_pubme%3E1841804426%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841804426&rft_id=info:pmid/27858509&rft_doaj_id=oai_doaj_org_article_4ecf33f225b145baa353648f5c6e19c6&rfr_iscdi=true |